ACC 26 Announces Late-Breaking Clinical Trial Sessions
SOURCE: American College of Cardiology
PUBLISHED:

The American College of Cardiology's 76th Annual Scientific Session (ACC.26) has announced its late-breaking clinical science program, featuring pivotal trial results across pulmonary embolism, atrial fibrillation, left main intervention, heart failure, lipid management, and structural heart disease.

These sessions will showcase practice-changing evidence presented by leading international investigators, with presentations scheduled across Saturday 28 March through Monday 30 March 2026.

Late-Breaking Clinical Science Session I

Saturday 28 March 2026, 09:30–10:22 CST

  • Ultrasound-facilitated Catheter-directed Thrombolysis vs Anticoagulation Alone for Acute Intermediate-High-Risk Pulmonary Embolism: Primary Results of the HI-PEITHO Randomized Clinical Trial – Presented by Dr Stavros Konstantinides
  • Outcomes in Patients with Atrial Fibrillation Randomized to Receive Left Atrial Appendage Closure or Oral Anticoagulation: Primary Results of the CHAMPION-AF Clinical Trial – Presented by Dr Saibal Kar

  • Primary Left Ventricular Unloading in Anterior ST-Segment Elevation Myocardial Infarction (STEMI) Without Cardiogenic Shock: Results from the STEMI-Door to Unload Randomized Clinical Trial – Presented by Dr Navin Kapur

     

Late-Breaking Clinical Science Session II

Saturday 28 March 2026, 15:45–16:40 CST

  • Kardinal: A Phase 2 Study of Tonlamarsen for the Treatment of Uncontrolled Hypertension – Presented by Dr Luke Laffin
  • Evolocumab in Patients Without Significant Atherosclerosis: Results from VESALIUS-CV – Presented by Dr Nicholas Marston
  • Intensive Low-Density Lipoprotein Cholesterol Targeting in Patients with Atherosclerotic Cardiovascular Disease – Presented by Dr Byeoung-Keuk Kim

  • DASH-Patterned Groceries to Reduce Blood Pressure Among Adults with Treated Hypertension: Results from the GoFreshRx Randomized Clinical Trial – Presented by Dr Stephen Juraschek

     

Late-Breaking Clinical Science Session III

Sunday 29 March 2026, 08:30–09:25 CST

  • Controlled Trial of High-Risk Coronary Intervention with Percutaneous Left Ventricular Unloading (CHIP-BCIS3) – Presented by Dr Divaka Perera
  • A Large-Scale, Global Randomized Trial of Coronary Physiology Derived from Conventional Angiography Compared with an Invasive Pressure Wire-Based Approach to Guide Percutaneous Coronary Intervention – Presented by Dr Ajay Kirtane
  • A Randomized, Placebo-Controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina: ORBITA-CTO Trial – Presented by Dr Sarosh Khan

  • Fractional Flow Reserve or 3D-Quantitative Coronary Angiography-Based Vessel-FFR Guided Revascularization: The FAST III Trial – Presented by Dr Joost Daemen

     

Late-Breaking Clinical Science Session IV

Sunday 29 March 2026, 10:45–11:40 CST

  • Spironolactone in the Treatment of Heart Failure – Presented by Dr Frank Edelmann
  • Efficacy and Safety of Sotatercept in Combined Post- and Pre-Capillary Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction: Results from the Phase 2 CADENCE Trial – Presented by Dr Mardi Gomberg-Maitland
  • Lung Impedance-Guided Therapy in Heart Failure with Preserved Ejection Fraction: Results of a Randomized Clinical Trial – Presented by Dr Michael Shochat

  • Mavacamten in Symptomatic Adolescent Patients with Obstructive Hypertrophic Cardiomyopathy: Results from the Phase 3 SCOUT-HCM Trial – Presented by Dr Joseph Rossano

     

Late-Breaking Clinical Science Session V

Sunday 29 March 2026, 16:00–16:55 CST

  • Redo-Surgery versus Transcatheter Valve-in-Valve for Mitral Bioprosthetic Dysfunction: The SURVIV Trial – Presented by Dr Dimytri Siqueira
  • Transcatheter Aortic Valve Implantation Without Routine Percutaneous Coronary Intervention: A Randomized Controlled Trial – Presented by Dr Michiel Voskuil
  • PROTECT the Head to Head Trial: Randomized Comparison of Emboliner Embolic Protection Catheter vs Sentinel Cerebral Protection System During Transcatheter Aortic Valve Replacement – Presented by Dr Adam Greenbaum

  • Two-Year Outcomes After Transcatheter Tricuspid Repair Without Cross-Over in the Randomized TRI-FR Trial – Presented by Dr Erwan Donal

     

Late-Breaking Clinical Science Session VI

Monday 30 March 2026, 08:30–09:25 CST

  • Heartline Study: A Decentralized Randomized Trial of Apple Watch and iPhone-Facilitated AF Detection and Cardiovascular Outcomes in Older Adults Without Known Atrial Fibrillation – Presented by Dr C. Michael Gibson
  • Digoxin in Rheumatic Heart Disease: A Multi-Center, Randomized, Double Blind, Placebo-Controlled Trial – Presented by Dr Ganesan Karthikeyan
  • Discontinuation of β-Blocker Therapy in Stabilized Patients After Acute Myocardial Infarction – Presented by Dr Joo-Yong Hahn

  • Effect of Intensive Triglyceride Lowering with Olezarsen on Progression of Coronary Atherosclerosis: A Coronary CTA Substudy of the ESSENCE-TIMI 73b Randomized Trial – Presented by Dr Nicholas Marston

     

Late-Breaking Clinical Science Session VII

Monday 30 March 2026, 10:45–11:40 CST

  • Primary Efficacy and Safety Results from the Phase 3 Sirolimus-Coated Balloon for Infra-Inguinal Peripheral Arterial Disease (SirPAD) Trial – Presented by Dr Stefano Barco
  • Intravascular Ultrasound Guidance for Complex High-Risk Indicated Procedures: The IVUS CHIP Trial – Presented by Dr Roberto Diletti
  • Intravascular Ultrasound-Guided versus Angiography-Guided Percutaneous Coronary Intervention in Unprotected Left Main Coronary Artery Disease: The OPTIMAL Trial – Presented by Dr Adrian Banning

  • IVUS or Angiography Guidance for PCI in Complex Coronary Bifurcation Lesions – Presented by Dr Shaoliang Chen

     

References

American College of Cardiology. ACC.26 Scientific Session Program. https://www.acc.org/ACC26 (accessed Friday 23rd January, 2026).

Share: